Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

2.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

3.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
4.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group.

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
5.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
6.

Breast cancer prevention trials.

Rhodes DJ, Hartmann LC, Perez EA.

Curr Oncol Rep. 2000 Nov;2(6):558-65. Review.

PMID:
11122893
7.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

8.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
9.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

10.

Current concepts in breast cancer chemoprevention.

Chlebowski RT.

Pol Arch Med Wewn. 2014;124(4):191-9. Epub 2014 Mar 10. Review.

11.

The use of tamoxifen and raloxifene for the prevention of breast cancer.

Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N.

Recent Results Cancer Res. 2009;181:113-9. Review.

12.

Chemoprevention of breast cancer in postmenopausal women.

Geller BA, Vogel VG.

Breast Dis. 2005-2006;24:79-92. Review.

PMID:
16917141
13.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Vogel VG.

Curr Drug Targets. 2011 Dec;12(13):1874-87. Review.

PMID:
21158712
14.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
15.

Chemoprevention or mastectomy for women at high risk of developing breast cancer.

Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N.

Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Epub 2015 Jul 26. Review.

PMID:
26276104
16.

Chemoprevention of breast cancer in the older patient.

Minton SE.

Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review.

PMID:
10680075
17.

The selective estrogen receptor modulators in breast cancer prevention.

Li F, Dou J, Wei L, Li S, Liu J.

Cancer Chemother Pharmacol. 2016 May;77(5):895-903. doi: 10.1007/s00280-016-2959-0. Epub 2016 Jan 20. Review.

PMID:
26787504
18.

Overview of the main outcomes in breast-cancer prevention trials.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.

Lancet. 2003 Jan 25;361(9354):296-300. Review.

PMID:
12559863
19.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
20.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927

Supplemental Content

Support Center